Rocuronium Bromide 10mg | 5mL Injectable MDV

AuroMedics Rocuronium Bromide is a non-depolarizing neuromuscular blocking agent used as an adjunct to general anesthesia to facilitate rapid sequence and routine endotracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Each 5mL multiple-dose vial (MDV) contains 10mg/mL of Rocuronium Bromide, ensuring precise and controlled administration for medical professionals.

Product Features:

• Potent Neuromuscular Blockade: Rocuronium Bromide is known for its rapid onset and intermediate duration of action, allowing for swift muscle relaxation and ease of intubation.
• Multiple-Dose Vial (MDV): The 5mL vial is designed to support multiple doses, providing versatility and cost-effectiveness for clinical use.
• Clear, Colorless Solution: Ensures ease of inspection for particulate matter and integrity, promoting safe administration.
• Compatible with a Range of Anesthetics: Can be used in conjunction with various anesthetic agents, providing flexibility in tailoring anesthesia protocols.

Intended Use:

AuroMedics Rocuronium Bromide Injectable is intended for use in various healthcare settings, such as operating rooms, intensive care units, and emergency departments. It is administered by or under the supervision of qualified healthcare professionals experienced in the use of neuromuscular blocking agents. The product is particularly valuable in surgeries requiring muscle relaxation, rapid sequence intubation, and in settings where mechanical ventilation is necessary.

Benefits:

• Rapid Onset: Provides effective muscle relaxation within 1-2 minutes, ideal for emergency intubations or surgical procedures.
• Intermediate Duration: Offers sufficient duration for various types of surgeries, reducing the need for frequent redosing.
• Precision and Control: Enables anesthesiologists to maintain control over neuromuscular function, ensuring patient safety during complex procedures.
• Reduced Histamine Release: Exhibits minimal histamine release, lowering the risk of adverse reactions such as bronchospasm or hypotension.